Quiros Juan Jose Chacon Sells 6,839 Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) CEO Quiros Juan Jose Chacon sold 6,839 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $45.30, for a total transaction of $309,806.70. Following the completion of the transaction, the chief executive officer now directly owns 218,896 shares of the company’s stock, valued at approximately $9,915,988.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Establishment Labs Trading Up 2.3 %

Shares of NASDAQ:ESTA opened at $43.73 on Friday. The firm has a fifty day moving average of $49.81 and a two-hundred day moving average of $43.85. The firm has a market capitalization of $1.20 billion, a P/E ratio of -13.93 and a beta of 1.24. Establishment Labs Holdings Inc. has a 12-month low of $16.96 and a 12-month high of $73.00. The company has a quick ratio of 2.73, a current ratio of 4.24 and a debt-to-equity ratio of 3.38.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The company had revenue of $37.17 million during the quarter, compared to analyst estimates of $35.61 million. Establishment Labs had a negative net margin of 53.12% and a negative return on equity of 206.05%. The company’s revenue for the quarter was down 20.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.48) EPS. On average, equities analysts expect that Establishment Labs Holdings Inc. will post -1.79 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ESTA. Mizuho raised their price objective on shares of Establishment Labs from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, June 6th. Citigroup lowered shares of Establishment Labs from a “buy” rating to a “neutral” rating and set a $60.00 price objective for the company. in a research note on Wednesday, May 22nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ESTA. Adage Capital Partners GP L.L.C. raised its holdings in shares of Establishment Labs by 17.2% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 80,000 shares of the company’s stock valued at $3,926,000 after purchasing an additional 11,736 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in shares of Establishment Labs by 16.3% during the 3rd quarter. Kennedy Capital Management LLC now owns 139,332 shares of the company’s stock valued at $6,837,000 after purchasing an additional 19,529 shares in the last quarter. Baker Avenue Asset Management LP bought a new position in shares of Establishment Labs during the 3rd quarter valued at $59,000. American Century Companies Inc. raised its holdings in shares of Establishment Labs by 1.4% during the 3rd quarter. American Century Companies Inc. now owns 282,292 shares of the company’s stock valued at $13,852,000 after purchasing an additional 3,831 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Establishment Labs during the 4th quarter valued at $120,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.